Drug Search Results
More Filters [+]

P-KLKB1-101

Alternative Names: P-KLKB1-101
Latest Update: 2024-05-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Gene Therapy

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Poseida
Company Location: SAN DIEGO CA 92121
Company CEO: Mark J. Gergen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for P-KLKB1-101

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Angioedemas, Hereditary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title